Jan B. Vermorken

18.7k total citations · 3 hit papers
371 papers, 12.8k citations indexed

About

Jan B. Vermorken is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Jan B. Vermorken has authored 371 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 212 papers in Oncology, 118 papers in Pulmonary and Respiratory Medicine and 92 papers in Otorhinolaryngology. Recurrent topics in Jan B. Vermorken's work include Head and Neck Cancer Studies (92 papers), Lung Cancer Treatments and Mutations (85 papers) and Cancer Treatment and Pharmacology (63 papers). Jan B. Vermorken is often cited by papers focused on Head and Neck Cancer Studies (92 papers), Lung Cancer Treatments and Mutations (85 papers) and Cancer Treatment and Pharmacology (63 papers). Jan B. Vermorken collaborates with scholars based in Belgium, Netherlands and United States. Jan B. Vermorken's co-authors include Herbert M. Pinedo, Filip Lardon, Manon Huizing, Godefridus J. Peters, Petr Szturz, Marc Baay, Gijsbert Veerman, Veronique W.T. Ruiz van Haperen, Lisa Licitra and Bea Pauwels and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jan B. Vermorken

367 papers receiving 12.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

2011 452 citations Jan B. Vermorken et al. profile →
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

2013 314 citations Jan B. Vermorken, Arlene A. Forastiere et al. profile →
Management of locally recurrent nasopharyngeal carcinoma

2019 223 citations Anne W.M. Lee, Wai Tong Ng et al. Cancer Treatment Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan B. Vermorken Belgium	59	7.0k	3.4k	3.1k	2.4k	2.3k	371	12.8k
Bhuvanesh Singh United States	59	5.7k 0.8×	4.8k 1.4×	4.7k 1.5×	3.2k 1.3×	1.8k 0.8×	169	13.6k
Brigette Ma Hong Kong	53	4.9k 0.7×	2.7k 0.8×	2.3k 0.8×	2.3k 1.0×	3.1k 1.4×	243	10.2k
Sandrine Faivre France	58	6.8k 1.0×	6.7k 2.0×	3.4k 1.1×	1.5k 0.6×	916 0.4×	286	14.9k
Winnie Yeo Hong Kong	63	6.5k 0.9×	2.6k 0.8×	2.7k 0.9×	2.5k 1.1×	812 0.4×	423	17.7k
William E. Gooding United States	75	7.4k 1.1×	5.0k 1.5×	4.3k 1.4×	3.1k 1.3×	2.3k 1.0×	283	17.2k
Aaron R. Hansen Canada	39	4.2k 0.6×	1.8k 0.5×	2.5k 0.8×	2.0k 0.8×	965 0.4×	328	7.8k
Roger B. Cohen United States	56	9.2k 1.3×	5.4k 1.6×	5.9k 1.9×	3.4k 1.4×	3.9k 1.7×	328	17.5k
Howard S. Höchster United States	56	8.1k 1.2×	2.4k 0.7×	3.3k 1.1×	1.8k 0.7×	405 0.2×	342	12.0k
Rosemarie Mick United States	72	6.2k 0.9×	3.5k 1.0×	2.6k 0.8×	2.0k 0.8×	808 0.4×	265	14.4k
Taylor Murray United States	6	4.5k 0.6×	3.8k 1.1×	3.3k 1.1×	2.0k 0.8×	296 0.1×	7	11.5k

Countries citing papers authored by Jan B. Vermorken

Since Specialization

Citations

This map shows the geographic impact of Jan B. Vermorken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan B. Vermorken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan B. Vermorken more than expected).

Fields of papers citing papers by Jan B. Vermorken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan B. Vermorken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan B. Vermorken. The network helps show where Jan B. Vermorken may publish in the future.

Co-authorship network of co-authors of Jan B. Vermorken

This figure shows the co-authorship network connecting the top 25 collaborators of Jan B. Vermorken. A scholar is included among the top collaborators of Jan B. Vermorken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan B. Vermorken. Jan B. Vermorken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saba, Nabil F., Karthik Rao, Robert P. Takes, et al.. (2025). Head and Neck Cancer Salvage Surgery in the Era of Immunotherapy and Beyond. JAMA Otolaryngology–Head & Neck Surgery. 151(11). 1091–1091.

Saba, Nabil F., Mayur D. Mody, Primož Strojan, et al.. (2023). Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers. 15(7). 1959–1959. 12 indexed citations

Bree, Remco de, György B. Halmos, Antti Mäkitie, et al.. (2022). Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty. Frontiers in Oncology. 12. 884988–884988. 16 indexed citations

Strojan, Primož, Aleš Grošelj, Gregor Serša, et al.. (2021). Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review. Cancers. 13(6). 1254–1254. 20 indexed citations

Stordeur, Sabine, Isabelle Savoye, Roos Leroy, et al.. (2020). Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study?. Oral Oncology. 102. 104561–104561. 24 indexed citations

Ng, Wai Tong, June Corry, Johannes A. Langendijk, et al.. (2020). Current management of stage IV nasopharyngeal carcinoma without distant metastasis. Cancer Treatment Reviews. 85. 101995–101995. 33 indexed citations

Pauw, Ines De, Filip Lardon, Jolien Van den Bossche, et al.. (2019). Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. Cancers. 11(1). 98–98. 14 indexed citations

Bossi, Paolo, Salvatore Alfieri, Primož Strojan, et al.. (2019). Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. Critical Reviews in Oncology/Hematology. 137. 84–91. 45 indexed citations

Bossche, Jolien Van den, Andreas Domen, Marc Peeters, et al.. (2019). Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers. 11(12). 1893–1893. 9 indexed citations

10.

Lee, Anne W.M., Wai Tong Ng, Jimmy Yu Wai Chan, et al.. (2019). Management of locally recurrent nasopharyngeal carcinoma. Cancer Treatment Reviews. 79. 101890–101890. 223 indexed citations breakdown →

11.

Bonner, James A., Ricard Mesı́a, J. Giralt, et al.. (2017). p16, HPV, and Cetuximab: What Is the Evidence?. The Oncologist. 22(7). 811–822. 17 indexed citations

12.

Tryfonidis, Konstantinos, Sandrine Marréaud, Hussein Khaled, et al.. (2017). Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast Cancer Research and Treatment. 163(3). 507–515. 2 indexed citations

13.

Pauw, Ines De, An Wouters, Jolien Van den Bossche, et al.. (2017). Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Cancer Biotherapy and Radiopharmaceuticals. 32(7). 229–238. 13 indexed citations

14.

Hengst, W., Jeroen Hendriks, Bram Balduyck, et al.. (2014). Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases. Journal of Thoracic Oncology. 9(10). 1547–1553. 23 indexed citations

15.

Cutsem, Eric Van, Sabine Tejpar, Dirk Vanbeckevoort, et al.. (2012). Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology. 30(23). 2861–2868. 94 indexed citations

16.

Peeters, Marc, Jan B. Vermorken, F. Viret, et al.. (2007). Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST).. Annals of Oncology. 18. 34. 4 indexed citations

17.

Wouters, An, Bea Pauwels, Cindy Simoens, et al.. (2006). In vitro interaction between pemetrexed and gemcitabine using different treatment schedules.. Cancer Research. 66. 1278–1279. 1 indexed citations

18.

Hoekman, Klaas, W. J. F. van der Vijgh, & Jan B. Vermorken. (1999). Clinical and Preclinical Modulation of Chemotherapy-Induced Toxicity in Patients with Cancer. Drugs. 57(2). 133–155. 41 indexed citations

19.

Giaccone, Giuseppe, Sabine C. Linn, Jan Welink, et al.. (1997). A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.. Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam). 3(11). 2005–15. 71 indexed citations

20.

Nijman, Hans W., Curt W. Burger, Jan P. A. Baak, et al.. (1992). Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. European Journal of Cancer. 28(12). 1971–1973. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact